$2.6 Billion is the total value of Cormorant Asset Management, LP's 93 reported holdings in Q3 2020. The portfolio turnover from Q2 2020 to Q3 2020 was 180.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| RVMD | Buy | REVOLUTION MEDICINES INC | $91,878,000 | +11.0% | 2,640,177 | +0.1% | 3.53% | +11.9% |
| IMVT | New | IMMUNOVANT INC | $57,639,000 | – | 1,637,951 | +100.0% | 2.22% | – |
| ZYME | Buy | ZYMEWORKS INC | $53,567,000 | +170.0% | 1,150,000 | +109.1% | 2.06% | +172.1% |
| OMER | Buy | OMEROS CORP | $50,525,000 | +23.7% | 5,000,000 | +80.2% | 1.94% | +24.6% |
| VIE | Buy | VIELA BIO INC | $44,507,000 | -32.1% | 1,585,000 | +4.8% | 1.71% | -31.6% |
| RETA | Buy | REATA PHARMACEUTICALS INCcl a | $43,839,000 | -29.8% | 450,000 | +12.5% | 1.69% | -29.2% |
| ALXO | New | ALX ONCOLOGY HLDGS INC | $35,959,000 | – | 971,770 | +100.0% | 1.38% | – |
| New | TRILLIUM THERAPEUTICS INC | $35,525,000 | – | 2,500,000 | +100.0% | 1.37% | – | |
| AKRO | Buy | AKERO THERAPEUTICS INC | $26,466,000 | +79.2% | 859,550 | +45.1% | 1.02% | +80.8% |
| ALBO | New | ALBIREO PHARMA INC | $23,359,000 | – | 700,000 | +100.0% | 0.90% | – |
| BNTX | Buy | BIONTECH SEsponsored ads | $22,410,000 | +91.9% | 325,000 | +85.7% | 0.86% | +93.3% |
| GLPG | Buy | GALAPAGOS NVspon adr | $18,471,000 | -5.2% | 130,000 | +31.2% | 0.71% | -4.4% |
| OTIC | New | OTONOMY INC | $13,129,000 | – | 3,241,800 | +100.0% | 0.50% | – |
| TCRR | New | TCR2 THERAPEUTICS INC | $12,192,000 | – | 600,000 | +100.0% | 0.47% | – |
| AKUS | Buy | AKOUOS INC | $11,206,000 | +5.0% | 499,991 | +0.0% | 0.43% | +5.9% |
| OMER | New | OMEROS CORPcall | $10,110,000 | – | 1,000,000 | +100.0% | 0.39% | – |
| TBPH | Buy | THERAVANCE BIOPHARMA INC | $9,611,000 | +357.9% | 650,072 | +550.1% | 0.37% | +362.5% |
| HSAQ | New | HEALTH SCIENCES ACQ CORP 2 | $8,800,000 | – | 800,000 | +100.0% | 0.34% | – |
| ITOS | New | ITEOS THERAPEUTICS INC | $8,635,000 | – | 350,000 | +100.0% | 0.33% | – |
| BCTG | New | BCTG ACQUISITION CORP | $8,365,000 | – | 800,000 | +100.0% | 0.32% | – |
| TARA | New | PROTARA THERAPEUTIC INC | $7,574,000 | – | 450,000 | +100.0% | 0.29% | – |
| RACA | New | THERAPEUTICS ACQUISITION COR | $7,190,000 | – | 500,000 | +100.0% | 0.28% | – |
| MORF | New | MORPHIC HLDG INC | $6,835,000 | – | 250,000 | +100.0% | 0.26% | – |
| FSDC | New | FS DEV CORP | $5,599,000 | – | 500,000 | +100.0% | 0.22% | – |
| SRNE | New | SORRENTO THERAPEUTICS INCcall | $5,575,000 | – | 500,000 | +100.0% | 0.21% | – |
| VSPRU | New | VESPER HEALTHCARE ACQSTN CORunit 99/99/9999 | $4,104,000 | – | 400,000 | +100.0% | 0.16% | – |
| PANAU | New | PANACEA ACQUISITION CORPunit 99/99/9999 | $3,000,000 | – | 250,000 | +100.0% | 0.12% | – |
| CRDF | New | CARDIFF ONCOLOGY INC | $2,483,000 | – | 175,000 | +100.0% | 0.10% | – |
Other managers
Other managers that, in addition to the filing manager(s), that filed the EDGAR filing(s):
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2020-11-16
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| QUOTIENT LTD | 30 | Q3 2021 | 4.3% |
| ASCENDIS PHARMA A/S | 30 | Q4 2022 | 4.8% |
| MINERVA NEUROSCIENCES INC | 29 | Q3 2021 | 4.4% |
| ACCELERON PHARMA INC | 28 | Q2 2021 | 3.4% |
| OMEROS CORP | 27 | Q3 2021 | 6.5% |
| MIRATI THERAPEUTICS INC | 25 | Q4 2022 | 7.6% |
| BLUEPRINT MEDICINES CORP | 25 | Q3 2021 | 3.6% |
| APELLIS PHARMACEUTICALS INC | 24 | Q3 2023 | 8.6% |
| NEUROCRINE BIOSCIENCES INC | 24 | Q1 2020 | 4.6% |
| ROCKET PHARMACEUTICALS, INC | 23 | Q3 2023 | 2.4% |
View Cormorant Asset Management, LP's complete holdings history.
Latest significant ownerships (13-D/G)
| Filed | Shares | Percentage | |
|---|---|---|---|
| Ambrx Biopharma Inc. | March 13, 2023 | 42,771,365 | - |
| Altimmune, Inc. | February 14, 2023 | 2,600,000 | - |
| Arcellx, Inc. | February 14, 2023 | 2,075,000 | - |
| BioAtla, Inc. | February 14, 2023 | 2,499,250 | - |
| Eledon Pharmaceuticals, Inc. | February 14, 2023 | 1,391,663 | - |
| GreenLight Biosciences Holdings, PBC | February 14, 2023 | 4,751,020 | - |
| Prometheus Biosciences, Inc. | February 14, 2023 | 700,000 | - |
| Tango Therapeutics, Inc. | February 14, 2023 | 1,000,000 | - |
| VectivBio Holding AG | February 14, 2023 | 1,515,087 | - |
| Viridian Therapeutics, Inc.\DE | February 14, 2023 | 1,100,000 | - |
View Cormorant Asset Management, LP's complete significant-ownership history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2024-05-08 |
| SC 13G | 2024-04-29 |
| 4 | 2024-04-22 |
| SC 13G/A | 2024-04-15 |
| 4 | 2024-04-03 |
| SC 13G | 2024-03-21 |
| 4 | 2024-03-18 |
| SC 13G/A | 2024-03-18 |
| 4 | 2024-03-11 |
| 13F-HR | 2024-02-14 |
View Cormorant Asset Management, LP's complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.